How long should apixaban (Eliquis) and clopidogrel (Plavix) be continued after transcatheter aortic valve replacement (TAVR)?

Duration of Apixaban (Eliquis) and Clopidogrel (Plavix) After TAVR

For patients without an existing indication for anticoagulation, continue clopidogrel 75 mg daily for 3-6 months after TAVR along with lifelong aspirin 75-100 mg daily, then discontinue clopidogrel and continue aspirin alone. For patients with atrial fibrillation or another indication for anticoagulation, use apixaban (or another anticoagulant) alone without adding clopidogrel beyond the initial 3-6 month period.

Standard Post-TAVR Antithrombotic Regimen

The evidence-based approach depends on whether you have a separate indication for anticoagulation:

Patients WITHOUT Atrial Fibrillation or Other Anticoagulation Indication

The standard regimen is dual antiplatelet therapy (DAPT), not apixaban plus clopidogrel. Current ACC/AHA guidelines recommend 1, 2:

• Clopidogrel 75 mg daily for 3-6 months (balloon-expandable valves typically 6 months; self-expanding valves typically 3 months)
• Aspirin 75-100 mg daily lifelong (started immediately and continued indefinitely)
• After 3-6 months: discontinue clopidogrel and continue aspirin alone

This recommendation carries a Class IIb indication, meaning it "may be reasonable" 2. The duration was based on clinical trial protocols rather than rigorous comparative studies 1.

Important caveat: Recent evidence suggests that aspirin alone (single antiplatelet therapy) may be superior to DAPT, with lower bleeding rates and no increase in thrombotic events 3, 4. However, guidelines have not yet been updated to reflect this.

Patients WITH Atrial Fibrillation or Other Anticoagulation Indication

Use apixaban (or appropriate anticoagulant) alone—do not routinely add clopidogrel beyond 3-6 months 1:

• First 3-6 months: Consider adding clopidogrel to anticoagulation only in high-risk patients (e.g., recent coronary stenting), but this significantly increases bleeding risk
• After 3-6 months: Continue anticoagulation alone without any antiplatelet therapy
• The 2022 guideline states: "there is no evidence to support continued antiplatelet use beyond the initial 3-6 months unless a patient is at an exceptionally high risk for stroke or has another indication for antiplatelet use" 5

Apixaban-Specific Considerations

Apixaban is NOT routinely recommended as the primary antithrombotic strategy immediately after TAVR in patients without AF. The evidence shows:

• Apixaban reduced subclinical valve thrombosis compared to antiplatelet therapy in the ATLANTIS trial 6
• However, apixaban was NOT superior to standard of care for clinical outcomes and was associated with more non-cardiovascular deaths 7
• The 2017 ACC/AHA guidelines give vitamin K antagonist (VKA) therapy a Class IIb recommendation for 3 months post-TAVR, but this applies to warfarin, not apixaban 8

For patients with AF requiring anticoagulation after TAVR:

• Apixaban is preferred over warfarin based on general AF guidelines 9
• Use standard AF dosing: 5 mg twice daily (or 2.5 mg twice daily if ≥2 of: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL) 10
• Continue indefinitely as monotherapy after the initial 3-6 month period

Critical Warnings About Triple Therapy

If you must combine apixaban with clopidogrel (e.g., recent coronary stenting plus AF), this creates extremely high bleeding risk:

• Triple therapy (anticoagulant + aspirin + clopidogrel) should be limited to maximum 1 week to 1 month in highest-risk patients 5
• After initial period, use dual therapy (apixaban + clopidogrel) without aspirin for up to 12 months total
• The addition of clopidogrel to TAVR anticoagulation "should not exceed 6 months" 5
• Always add a proton pump inhibitor for GI bleeding prophylaxis 5

Practical Algorithm

Step 1: Determine if patient has AF or other anticoagulation indication

• NO: Use clopidogrel + aspirin for 3-6 months → aspirin alone lifelong
• YES: Proceed to Step 2

Step 2: Assess coronary stent status

• No recent stent: Apixaban alone (no clopidogrel, no aspirin)
• Recent stent: Apixaban + clopidogrel (no aspirin) for up to 6 months → apixaban alone

Step 3: At 3-6 months post-TAVR

• Discontinue all antiplatelet therapy in patients on anticoagulation
• Continue anticoagulation indefinitely for AF indication

Common Pitfalls to Avoid

• Do not continue DAPT beyond 6 months in patients without coronary disease—bleeding risk outweighs benefit
• Do not use apixaban as primary strategy in patients without AF—this is not guideline-supported
• Do not combine apixaban with dual antiplatelet therapy for extended periods—triple therapy dramatically increases bleeding
• Do not use DOACs in mechanical valves—this is contraindicated 2, 10
• Do not assume longer is better—extended antiplatelet therapy increases bleeding without reducing thrombotic events 3, 4

The evidence base remains limited, with most recommendations based on clinical trial protocols rather than head-to-head comparisons. The trend is toward shorter durations and less intensive regimens to reduce bleeding complications 1.